Oxandrolone and Turinabol Interaction: Avoid | Peptide Database

The 2019 Isenmann et al. study at Freie Universitat Berlin demonstrated that ecdysterone supplementation (administered as spinach extract standardized to ecdysterone content) produced significantly greater increases in lean muscle mass compared to placebo over 10 weeks of resistance training in young, trained men. The highest-dose group gained approximately 2 kg more lean mass than placebo. These results, combined with earlier Soviet-era research and multiple animal studies, support ecdysterone as a meaningful natural anabolic agent. Participants in the Berlin study also showed greater improvements in one-repetition maximum bench press compared to placebo. Animal studies have demonstrated improved grip strength, endurance capacity, and force production with ecdysterone administration. The mechanism likely involves both increased muscle protein synthesis and improved calcium handling within muscle fibers, enhancing contractile efficiency. Preclinical evidence suggests ecdysterone accelerates recovery from exercise-induced muscle damage through anti-inflammatory effects and enhanced protein synthesis rates. Users frequently report reduced delayed-onset muscle soreness (DOMS) and improved training frequency tolerance. However, dedicated human recovery studies are limited. By promoting lean mass accretion without androgenic hormonal disruption, ecdysterone may support body recomposition (simultaneous fat loss and muscle gain) particularly in trained individuals on a structured nutrition plan. Some animal data suggest mild lipolytic effects, though this has not been convincingly demonstrated in human trials.

Join others researching Abaloparatide — share findings, ask questions, and learn from real experiences Abaloparatide is an FDA-approved anabolic bone-building agent and synthetic analog of parathyroid hormone-related protein (PTHrP). It selectively activates the PTH1 receptor to stimulate new bone formation while minimizing bone resorption. In the phase III ACTIVE trial, abaloparatide showed superior BMD increases at the hip compared to teriparatide, with substantial fracture risk reduction. It was approved in the US in 2017 and EU in 2022 for postmenopausal women and men with osteoporosis at high fracture risk. Abaloparatide works through selective activation of the parathyroid hormone 1 receptor (PTH1R), a G protein-coupled receptor expressed on osteoblasts and osteocytes. It preferentially binds to the RG (relaxed, G-protein-coupled) conformational state of PTH1R, which elicits a transient downstream cyclic AMP signaling response favoring anabolic bone formation over resorption. This selective binding pattern produces more bone-building activity with less hypercalcemic effect compared to native PTH. The result is increased cortical and trabecular bone volume, density, and improved microarchitecture.